文献速递骨质疏松与代谢性骨病

高度依从阿仑膦酸治疗患者中经手术治疗的颌骨及口腔骨坏死与骨髓炎:一项纳入逾6万名阿仑膦酸使用者的全国性使用者队列研究

Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
PubMed 文献 · Osteoporos Int · 2017-06-29

该研究基于丹麦全国注册数据,纳入1996-2007年首次使用阿仑膦酸的50-94岁患者61990例,随访至2013年12月31日。平均6.8年随访中,107例因颌骨骨坏死(ONJ)或相关情况接受手术,发病率为2.53/10000人年(95%CI 2.08-3.05)。近期使用、长期使用及高依从性与手术治疗的ONJ风险升高相关,但绝对风险仍低。

要点

  • 阿仑膦酸使用者中经手术治疗的ONJ发病率为2.53/10000人年(95%CI 2.08-3.05)。
  • 近期使用较既往使用的校正OR为4.13(95%CI 1.94-8.79)。
  • 高依从性(MPR>50%)较低依从性(MPR<50%)ONJ风险增加2至3倍,长期使用(>5年)校正OR为2.31(95%CI 1.14-4.67)。

核心结论

  • 数据提示近期、长期及依从性良好的阿仑膦酸使用与经手术治疗的ONJ风险增加相关。
  • 即便如此,即使在长期依从使用者中,ONJ发生率仍然较低。
  • ONJ风险在可能间接影响口腔黏膜的疾病患者中似乎更高。

研究设计与样本

  • 开放全国注册登记队列研究,并包含一项巢式病例对照研究。
  • 研究对象为丹麦1996-2007年首次使用阿仑膦酸的初治患者,男女均可,开始治疗时年龄50-94岁,共61990例。
  • 随访至2013年12月31日。

主要发现

  • 平均随访6.8年期间,107例患者因ONJ或相关情况接受手术,发病率为2.53/10000人年(95%CI 2.08-3.05)。
  • 近期使用较既往使用的校正OR为4.13(95%CI 1.94-8.79)。
  • 高依从性(MPR>50%)使用者较低依从性(MPR<50%)使用者的ONJ风险增加2至3倍。
  • 长期使用(>5年)较短期使用的校正OR为2.31(95%CI 1.14-4.67)。
  • 风湿性疾病史和质子泵抑制剂使用与经手术治疗的ONJ独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteonecrosis of the jaw (ONJ) is rare (2.53/10,000 person-years) among alendronate users, but long-term and compliant use are associated with an increased risk of surgically treated ONJ. Risk of surgically treated ONJ is higher in patients with rheumatoid diseases and use of proton pump inhibitors. INTRODUCTION: ONJ is a rare event in users of oral bisphosphonates. Our aims were to evaluate if the risk of surgically treated ONJ increases with longer or more compliant treatment with alendronate for osteoporosis and to identify risk factors for surgically treated ONJ. METHODS: Open nationwide register-based cohort study containing one nested case-control study. Patients were treatment-naïve incident users of alendronate 1996-2007 in Denmark, both genders, aged 50-94 at the time of beginning treatment (N = 61,990). Participants were followed to 31 December 2013. RESULTS: Over a mean of 6.8 years, 107 patients received surgery for ONJ or related conditions corresponding to an incidence rate of 2.53 (95% confidence interval (CI) 2.08 to 3.05) per 10,000 patient years. Recent use was associated with an adjusted odds ratio (OR) 4.13 (95% CI 1.94 to 8.79) compared to past use. Similarly, adherent users (medication possession ratio (MPR) >50%) were at two to threefold increased risk of ONJ compared to low adherence (MPR <50%), and long-term (>5 years) use was related with higher risk (adjusted OR 2.31 (95% CI (1.14 to 4.67)) than shorter-term use. History of rheumatoid disorders and use of proton pump inhibitors were independently associated with surgically treated ONJ. CONCLUSIONS: Our data suggest that recent, long-term, and compliant uses of alendronate are associated with an increased risk of surgically treated ONJ. Nevertheless, the rates remain low, even in long-term adherent users. ONJ risk appears higher in patients with conditions likely to indirectly affect the oral mucosa.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Eiken PA, Prieto-Alhambra D, Eastell R, et al. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. Osteoporos Int. 2017. PMID: 28664276. doi:10.1007/s00198-017-4132-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。